Dr. Hope on Imaging for Neuroendocrine Tumors

Video

Thomas Hope, MD, assistant professor, UCSF Helen Diller Family Comprehensive Cancer Center, discusses imaging for patients with neuroendocrine tumors (NETs).

Thomas Hope, MD, assistant professor, UCSF Helen Diller Family Comprehensive Cancer Center, discusses imaging for patients with neuroendocrine tumors (NETs).

Imaging of NETs is difficult because they grow slowly over time and conventional PET imaging, using glucose or FDG-PET scan, has low-detection sensitivity, explains Hope.

There have recently been PET scans that use somatostatin receptor-targeted agents, most notably being DOTATOC and DOTATATE PET imaging, which are labeled with Gallium-68. These imaging modalities have demonstrated much higher sensitivity for the detection and characterization of NETs, states Hope.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,